Takeda Pharmaceutical Company Limited TKPHF
OTC PK
| 09/30/2026 | 06/30/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -2.55% | 9.78% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -2.55% | 9.78% | |||
| Cost of Revenue | -3.45% | -11.64% | |||
| Gross Profit | -2.10% | 24.92% | |||
| SG&A Expenses | -5.03% | -3.34% | |||
| Depreciation & Amortization | -22.06% | -0.05% | |||
| Other Operating Expenses | -140.53% | 181.48% | |||
| Total Operating Expenses | -12.00% | 3.18% | |||
| Operating Income | 45.48% | 62.56% | |||
| Income Before Tax | -4.01% | 135.22% | |||
| Income Tax Expenses | -173.88% | 156.25% | |||
| Earnings from Continuing Operations | 70.17% | 130.28% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 51.59% | 4.68% | |||
| Net Income | 70.24% | 130.26% | |||
| EBIT | 45.48% | 62.56% | |||
| EBITDA | 25.54% | 85.85% | |||
| EPS Basic | 68.65% | 130.26% | |||
| Normalized Basic EPS | 48.38% | 123.22% | |||
| EPS Diluted | 68.56% | 129.80% | |||
| Normalized Diluted EPS | 48.33% | 119.78% | |||
| Average Basic Shares Outstanding | 0.95% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.99% | 1.56% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -0.97% | 56.62% | |||